Skip to main content
Premium Trial:

Request an Annual Quote

Edico Genome Raises $10M to Commercialize Informatics Product

NEW YORK (GenomeWeb) – Edico Genome said today that it raised $10 million in a Series A round of financing that it will use to commercialize its Dragen Bio-IT Processor, an application-specific integrated circuit system for next-generation sequence data analysis.

The financing round was led by Qualcomm through its venture investment group Qualcomm Ventures. The list of investors includes Axon Ventures and Greg Lucier, former Life Technologies chairman and CEO. As part of his investment, Lucier has joined Edico Genome's board of directors.

Edico plans to launch Dragen at the American Society of Human Genetics annual meeting in October. The processor is embedded on a PCIe form factor card that can be integrated into sequencing machines and servers. It comes preloaded with highly optimized algorithms for mapping, alignment, sorting, and variant calling.

According to Edico, Dragen reduces the computational time needed to analyze a whole human genome from 24 hours to 18 minutes. It also reduces the need for large clusters to process data and by extension reduces storage and infrastructure spending.

"Advancing and expanding the use of genomics in the clinic can only be achieved if researchers and physicians can quickly, efficiently, and accurately process the immense amount of data generated from a human genome sequence," Lucier said in a statement. "Edico Genome's solution to speed data analysis and lower costs has the potential to have a large impact on many areas of medicine, particularly in oncology and non-invasive prenatal testing."

Filed under

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.